Squarepoint’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.04M Buy
+249,482
New +$1.01M ﹤0.01% 2754
2025
Q3
Sell
-26,034
Closed -$86.2K 4338
2025
Q2
$86.2K Buy
+26,034
New +$74.7K ﹤0.01% 4205
2024
Q4
Sell
-85,392
Closed -$425K 5001
2024
Q3
$425K Buy
85,392
+51,991
+156% +$202K ﹤0.01% 3216
2024
Q2
$86.8K Sell
33,401
-5,845
-15% -$19.5K ﹤0.01% 3821
2024
Q1
$167K Buy
+39,246
New +$131K ﹤0.01% 3671
2023
Q4
Sell
-75,683
Closed -$116K 3982
2023
Q3
$116K Sell
75,683
-47,824
-39% -$82.2K ﹤0.01% 3541
2023
Q2
$204K Buy
123,507
+107,965
+695% +$195K ﹤0.01% 3216
2023
Q1
$17.7K Buy
+15,542
New +$13.5K ﹤0.01% 3138
2021
Q3
Sell
-19,824
Closed -$79K 2881
2021
Q2
$79K Buy
+19,824
New +$79.2K ﹤0.01% 3056
2021
Q1
Sell
-42,797
Closed -$229K 3081
2020
Q4
$229K Buy
+42,797
New +$256K ﹤0.01% 2415
2020
Q3
Sell
-193,856
Closed -$942K 2473
2020
Q2
$942K Buy
193,856
+177,431
+1,080% +$817K 0.02% 982
2020
Q1
$36K Sell
16,425
-2,225
-12% -$8.45K ﹤0.01% 1742
2019
Q4
$109K Sell
18,650
-22,127
-54% -$115K ﹤0.01% 2331
2019
Q3
$130K Buy
40,777
+2,587
+7% +$9.69K ﹤0.01% 2155
2019
Q2
$160K Buy
38,190
+22,190
+139% +$114K ﹤0.01% 2151
2019
Q1
$111K Sell
16,000
-13,828
-46% -$96.9K ﹤0.01% 2026
2018
Q4
$188K Buy
+29,828
New +$377K ﹤0.01% 1703

Other funds holding AQST

Squarepoint's AQST Position: Q1 2026 in Review

Squarepoint opened a new position in Aquestive Therapeutics (AQST) in Q1 2026: 249,482 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #2754 among its holdings. This is a return to the name: Squarepoint previously reported a position in AQST as recently as Q2 2025.

Squarepoint first reported a position in AQST in Q4 2018 and has held it in 17 quarters since. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Squarepoint held 249,482 shares of Aquestive Therapeutics worth $1.04M as of Q1 2026.
  • Aquestive Therapeutics was a new Squarepoint position in Q1 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2754 holding.
  • Squarepoint first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 17 quarters since.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.